REGENT PACIFIC GROUP LIMITED



(Incorporated in the Cayman Islands with Limited Liability)

Stock Code: 0575 28 February 2017

ANNOUNCEMENT

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

OPERATIONS UPDATE

SUMMARY

This announcement is made by the Company in compliance with the disclosure requirements under Rule 13.09 of the HK Listing Rules.

By way of an operations update, the Directors of the Company are pleased to announce that: (i) the Company, on behalf of Plethora, has formally approached the Hong Kong Department of Health indicating its intention to apply for the registration of Fortacin™ for sale as a pharmaceutical product in Hong Kong; (ii) following the UK launch, Fortacin™ can now be prescribed from a physician either in person or online via an online consultation, with prescriptions to be filled by Chemist 4 U (https://www.chemist-4-u.com/); (iii) discussions and negotiations are continuing to take place in respect of 'out licensing' the grant of rights in respect of Fortacin™ with pharmaceutical companies and with other strategic partners in other major territories outside of the UK and EU, including China; and (iv) in light of the successful Type IB variation applied for and approved with the EMA in 2016 in respect of the regulatory approved dose of each can of Fortacin™ to be sold in the EU, the pre-existing licence and development, manufacturing and supply agreements are to be amended to reflect the current state of play.

Regent Pacific Group Limited
8th Floor, Henley Building
5 Queen's Road Central
Hong Kong

Tel: (852) 2514 6111
Fax: (852) 2810 4792 | (852) 2509 0827
Email: info@regentpac.com
Website: www.regentpac.com

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

This announcement is made by Regent Pacific Group Limited (the "**Company**" and collectively with its subsidiaries, the "**Group**") in compliance with the disclosure requirements under Rule 13.09 of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**HK Listing Rules**").

Intention to apply for the registration of Fortacin™ in Hong Kong

The directors (the "**Directors**" or the "**Board**") of the Company are pleased to announce that, following work undertaken with the Company's regulatory consultants, the Company has formally approached the Hong Kong Department of Health indicating its intention to apply for the registration of Fortacin™ for sale as a pharmaceutical product in Hong Kong for and on behalf of Plethora Solutions Limited ("**Plethora**"). The Hong Kong Department of Health has very clear criteria and guidelines in respect of what is involved to successfully register Fortacin™ for sale as a pharmaceutical product in Hong Kong, and the Company has every intention of diligently working with its regulatory consultants to meet these criteria. Importantly, the Company understands that the existing European Medicines Agency ("**EMA**") approval of Fortacin™ is pivotal to the process, rendering the task more documentary in nature, rather than requiring further clinical trial work. Of course, much remains at the discretion of the Hong Kong Department of Health, but the Company is committed to working through the necessary steps to achieve a successful Hong Kong registration for Plethora. While it is too early to predict with any certainty when a successful registration can or could be made, the Company will update shareholders and the market more generally upon the satisfaction (or otherwise) of key milestones.

Update on UK and European Launches

With the launch of Fortacin™ in the UK, Plethora, a wholly owned subsidiary of the Company, has set up the prescription supply chain with Crawfords / JJS Pharma whereby males suffering from premature ejaculation in the UK can now seek a prescription from their physician and these prescriptions will be filled by the online pharmacy Chemist 4 U (https://www.chemist-4-u.com/). Patients will also shortly be able to go direct via the online prescription platform Doctor 4 U (http://doctor-4-u.co.uk/), where Fortacin™ will be listed and can be prescribed after an online consultation. Both Doctor 4 U and Chemist 4 U are run by Innox Trading Limited, which is a leading online multi-channel

retailer. Innox is the pharmacy behind other online clinical sites, which will expand the availability of Fortacin™.

In preparation of the commercial launch, process validation activities were undertaken at Pharmaserve North-West Ltd's ("**Pharmaserve**") commercial facilities and 3 GMP (good manufacturing practice) batches were manufactured on its commercial manufacturing line. In addition, stability studies on the three 12 dose GMP batches have been completed at the 3 month, 6 month and 9 month time points and one of the three batches at the 12 month time point, with only 2 batches remaining to be reported at the 12 month time point. Once the remaining 2 batches have been completed at Catalent Pharma Solutions Ltd., UK by the end of March 2017, this will allow Recordati S.p.A ("**Recordati**") to launch the 12 dose product in Europe in late 2017 (provided that the remaining two batches that are on stability at the 12 month time point remain within specification). Stability studies with the 12 dose product will continue to the end of the registered shelf life at 18 months with the aim of supporting registration of Fortacin™ in additional non-European markets.

The Company will update shareholders and the market more generally if and when there are any relevant developments in this respect.

Update on 'out licensing'

As previously disclosed, discussions and negotiations are continuing to take place in respect of 'out licensing' the grant of rights by Plethora with pharmaceutical companies and with other strategic partners in respect of Fortacin™ in other major territories outside of the UK and EU, including China. While it remains impossible to determine with accuracy the timing of completion of such agreements (and no assurance can be given that negotiations will lead to a binding licence agreement(s)), the Company anticipates that such discussions and negotiations will be assisted by Fortacin™ being brought to market in mainland Europe, which is expected to occur later in 2017. The Company will update shareholders and the market more generally if and when there are any relevant developments in this respect.

Anticipated revisions following revised dosage

In a further update, the Directors wish to inform shareholders that, in light of the successful Type IB variation applied for and approved with the EMA in 2016, having changed the regulatory approved dose of each can of Fortacin™ to be sold in the EU to not less than 12 doses/can, from 6 doses/can as previously foreshadowed, the pre-existing agreements with Recordati, in respect of the licence agreement, and Pharmaserve, in respect of the development, manufacturing and supply, do require amendment to reflect the current state of play. The Company is engaged in ongoing discussions with these parties and will announce any

material changes to the existing agreements, required in light of the revised dosage, as and when such changes are agreed.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

On Behalf of the Board of
Regent Pacific Group Limited

Jamie Gibson
Director

Directors of the Company:
James Mellon *(Chairman)*[*]
Jamie Gibson *(Chief Executive Officer)*
David Comba[#]
Julie Oates[#]
Mark Searle[#]
Jayne Sutcliffe[*]

[*] *Non-Executive Directors*
[#] *Independent Non-Executive Directors*

Hong Kong, 28 February 2017